SDC1 and plasma cell myeloma: Although on-target, off-tumor effects remain a concern due to CD138 expression in epithelial cells, ongoing optimization in these approaches could lead to significant advances in cell therapies for multiple myeloma, potentially improving survival outcomes for this difficult-to-treat malignancy (14).